SU6656

Catalog No.S7774 Batch:S777401

Print

Technical Data

Formula

C19H21N3O3S
Molecular Weight 371.45 CAS No. 330161-87-0
Solubility (25°C)* In vitro DMSO 74 mg/mL (199.21 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description SU 6656 is a selective Src family kinase inhibitor with IC50 of 280 nM, 20 nM, 130 nM, and 170 nM for Src, Yes, Lyn, and Fyn, respectively.
Targets
YES [1] Lyn [1] Fyn [1] Src [1]
20 nM 130 nM 170 nM 280 nM
In vitro

In NIH 3T3 cells, SU 6656 inhibits the PDGF-stimulated S-phase induction with IC50 of 0.3-0.4 μM. SU 6656 also inhibits PDGF- and serum-mediated NIH 3T3 cell proliferation, as well as epidermal growth factor and colony-stimulating factor 1-stimulated DNA synthesis in normal and colony-stimulating factor 1 receptor transfected NIH 3T3 cells. SU6656 inhibits PDGF-stimulated c-Myc induction and ERK2 activation.[1] Pretreating Jurkat T-cells with SU 6656 leads to increased VSV-G luciferase activity.[2] SU 6656 impairs TGF-β-mediated upregulation of CTGF mRNA and protein in proximal epithelial HKC-8 cells, and also reduces CTGF expression in cells exposed to autocrine growth factors. SU 6656 interferes with Aurora kinase activity resulting in inhibition of cell division and formation multilobular nuclei.[3]
In vivo

SU 6656 markedly and dose-dependently attenuates -induced experimental nicotine withdrawal syndrome in mice measured in terms of WSS and anxiety score.[4]

Protocol (from reference)

Kinase Assay:

[1]
  • Biochemical kinase assays for IC50 determination and kinetic studies

    IC50 measurements are made using poly-Glu–Tyr (4:1), or, in the case of Lck, poly-Lys–Tyr (4:1) as a peptide substrate. The divalent cation is 20 mM MgCl2 (in the case of Src, Fyn, Yes, Lyn, Csk, Frk, or Abl) or 10 mM MnCl2 (in the case of FGFR1, IGF1R, Lck, or Met). The final ATP concentrations are as follows: Src, 10 μM; Fyn, 6 μM; Yes, 100 μM; Lyn, 2 μM; Csk, 10 μM; Frk, 10 μM; Abl, 4 μM; FGFR1, 10 μM; IGF1R, 2 μM; Lck, 2 μM; Met, 5 μM; PDGFR, 6 μM. IC50 measurements of PDGFRb autophosphorylation are determined on immunoprecipitated PDGFRb. Km values are calculated using the Eadie-Hofstee method.
Cell Assay:

[3]
  • Cell lines

    HKC-8 cells

  • Concentrations

    5 μM

  • Incubation Time

    48 h

  • Method

    HKC-8 cells are seeded at different cells densities (10,000 cells/cm2 and 50,000 cells/cm2) and cultured in the presence or absence of SU 6656 for 24 and 48 h. Bright field pictures of cells are recorded by Olympus CK40 microscope using Leica DC Viewer software.
Animal Study:

[4]
  • Animal Models

    Inbred Swiss albino male mice

  • Dosages

    3 mg/kg

  • Administration

    i.p.

Customer Product Validation

, , Exp Cell Res, 2017, 358(2):360-368

Data from [Data independently produced by , , J Virol, 2015, 90(1):9-21]

Data from [Data independently produced by , , J Biol Chem, 2014, 289(18):12313-29.]

Selleck's SU6656 has been cited by 32 publications

CD28-CAR-T cell activation through FYN kinase signaling rather than LCK enhances therapeutic performance [ Cell Rep Med, 2023, S2666-3791(23)00002-2] PubMed: 36696897
Direct regulation of FNIP1 and FNIP2 by MEF2 sustains MTORC1 activation and tumor progression in pancreatic cancer [ Autophagy, 2023, 1-20.] PubMed: 37772772
Drug-repurposing screen on patient-derived organoids identifies therapy-induced vulnerability in KRAS-mutant colon cancer [ Cell Rep, 2023, 42(4):112324] PubMed: 37000626
Adjuvant activity of tubeimosides by mediating the local immune microenvironment [ Front Immunol, 2023, 14:1108244] PubMed: 36845089
Inhibition of Oncogenic Src Ameliorates Silica-Induced Pulmonary Fibrosis via PI3K/AKT Pathway [ Int J Mol Sci, 2023, 24(1)774] PubMed: 36614217
Dynamic changes in O-GlcNAcylation regulate osteoclast differentiation and bone loss via nucleoporin 153 [ Bone Res, 2022, 10(1):51] PubMed: 35879285
The Lectin LecB Induces Patches with Basolateral Characteristics at the Apical Membrane to Promote Pseudomonas aeruginosa Host Cell Invasion [ mBio, 2022, 13(3):e0081922] PubMed: 35491830
Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer [ Nat Commun, 2021, 12(1):2699] PubMed: 33976188
A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma [ Neuro Oncol, 2021, noab158] PubMed: 34232320
Siglec-8 Signals Through a Non-Canonical Pathway to Cause Human Eosinophil Death In Vitro [ Front Immunol, 2021, 12:737988] PubMed: 34721399

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.